Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
11/03/24	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
29/01/24	CoTec Holdings Outlines Key Targets For 2024	MT
04/01/24	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
10/10/23	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
10/10/23	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
02/10/23	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
14/09/23	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
14/09/23	CoTec Holdings, Mkango To Form US Joint Venture	MT
30/06/23	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
01/09/16	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
29/08/16	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
15/08/16	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
12/08/16	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	-3.19%	-3.19%	+44.60%	+87.98%	74.68B
ARGENX SE	-15.86%	-16.67%	+3.92%	+50.90%	58.7B
LONZA GROUP AG	-2.39%	-2.05%	+4.29%	+31.33%	48.36B
REVOLUTION MEDICINES, INC.	-6.35%	-8.35%	+303.95%	+651.28%	43.05B
IQVIA HOLDINGS INC.	+0.30%	-3.71%	+28.89%	+30.33%	42.48B
BEONE MEDICINES AG	-3.82%	-4.32%	+2.49%	+101.36%	41.39B
CELLTRION, INC.	-2.13%	+1.07%	+7.51%	+50.31%	31.29B
BIONTECH SE	-3.35%	-6.35%	-13.20%	-17.22%	23.93B
INSMED INCORPORATED	-1.24%	-11.97%	-38.10%	+311.13%	22.22B
Average	-3.79%	-2.63%	+38.26%	+144.16%	42.9B
Weighted average by Cap.	-4.84%	-1.88%	+44.70%	+136.42%

Employees

Sector